A Case of 1-Month Fever Caused by CMV Infection in a Patient With MIS-C Treated With IVIG, Infliximab, and High-Dose Methylprednisolone
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of coronavirus disease 2019 (COVID-19), causing multi-organ damage affecting the heart, lungs, kidneys, digestive tract, and nervous system. As the cases of MIS-C have been increasing following the COVID-19 pandemic, the importance of appropriate management for MIS-C is becoming increasingly apparent. Immunomodulating agents such as anakinra, infliximab, and steroids are regarded as supplementary therapy to the first-line treatment with intravenous immunoglobulin. However, these immunomodulating therapies can potentially precipitate opportunistic infections, including those caused by cytomegalovirus (CMV), Epstein-Barr virus, and tuberculosis, or increase the risk of co-infections. Herein, we report a case of a 3-year-old boy who was treated with immunoglobulin, infliximab, and high-dose methylprednisolone for MIS-C, and subsequently developed a persistent fever lasting 32 days caused by a CMV infection.
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a rare complication of coronavirus disease 2019 (COVID-19), causing multi-organ damage affecting the heart, lungs, kidneys, digestive tract, and nervous system. As the cases of MIS-C have been increasing following the COVID-19 pandemic, the importance of appropriate management for MIS-C is becoming increasingly apparent. Immunomodulating agents such as anakinra, infliximab, and steroids are regarded as supplementary therapy to the first-line treatment with intravenous immunoglobulin. However, these immunomodulating therapies can potentially precipitate opportunistic infections, including those caused by cytomegalovirus (CMV), Epstein-Barr virus, and tuberculosis, or increase the risk of co-infections. Herein, we report a case of a 3-year-old boy who was treated with immunoglobulin, infliximab, and high-dose methylprednisolone for MIS-C, and subsequently developed a persistent fever lasting 32 days caused by a CMV infection.
참고문헌 (20)
- Riphagen S, "Hyperinflammatory shock in children during COVID-19 pandemic", Lancet, 395, pp.1607~1608 (2020)
- Dufort EM, "Multisystem inflammatory syndrome in children in New York State", N Engl J Med, 383, pp.347~358 (2020)
- Sobh A, "How multisystem inflammatory syndrome in children discriminated from Kawasaki disease : a differentiating score based on an inception cohort study", Clin Rheumatol, 42, pp.1151~1161 (2023)
- Giacalone M, "Multisystem inflammatory syndrome in children(MIS-C) : a mini-review", Int J Emerg Med, 14, pp.50~ (2021)
- ")" (2022)[URL]
- Andersen NN, "Risk of infections associated with biological treatment in inflammatory bowel disease", World J Gastroenterol, 20, pp.16014~16019 (2014)
- Ali T, "Clinical use of anti-TNF therapy and increased risk of infections", Drug Healthc Patient Saf, 5, pp.79~99 (2013)
- Koritala T, "Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19 : a narrative review", Infez Med, 29, pp.495~503 (2021)
- Kobayashi T, "A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population", J Am Soc Echocardiogr, 29, pp.794~801 (2016)
- Henderson LA, "American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19 : version 1", Arthritis Rheumatol, 72, pp.1791~1805 (2020)
- Kim H, "Multisystem inflammatory syndrome in children related to COVID-19 : the first case in Korea", J Korean Med Sci, 35, pp.e391~ (2020)
- "COVID-19 antibody positive rate in Korea" (2022)[URL]
- "Multisystem inflammatory syndrome in children and adolescents with COVID-19" (2020)[URL]
- "CSTE/CDC Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection surveillance case report from guidance, effective January 1, 2023" (2023)[URL]
- Shana GC, "COVID-19-associated multisystem inflammatory syndrome in children – United States, March-July 2020", MMWR Morb Mortal Wkly Rep, 69, pp.1074~1080 (2020)
- Choi SR, "Changes in cytomegalovirus seroprevalence in Korea for 21 years : a single center study", Pediatr Infect Vaccine, 25, pp.123~131 (2018)
- Chou S, "Newer methods for diagnosis of cytomegalovirus infection", Rev Infect Dis, 12(Suppl 7), pp.S727~S736 (1990)
- Vella LA, "Current insights into the pathophysiology of multisystem inflammatory syndrome in children", Curr Pediatr Rep, 9, pp.83~92 (2021)
- Yamaguchi Y, "Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child", J Infect Chemother, 28, pp.814~818 (2022)
- Strangfeld A, "Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents", JAMA, 301, pp.737~744 (2009)